Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,433.20 24.66 0.15%
S&P 500 1,868.89 4.04 0.22%
NASDAQ 4,107.43 11.92 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

FDA Designations to Development Programs and Quarterly Financial Results Schedules - Research Report on Valeant, Elan, Alkermes,



   FDA Designations to Development Programs and Quarterly Financial Results
   Schedules - Research Report on Valeant, Elan, Alkermes, Teva and Gilead

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 23, 2013

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant
Pharmaceuticals Intl. Inc. (NYSE: VRX), Elan Corporation, plc. (NYSE: ELN),
Alkermes Plc. (NASDAQ; ALKS), Teva Pharmaceuticals Industries Ltd. (NYSE:
TEVA) and Gilead Sciences, Inc. (NASDAQ: GILD). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Valeant Pharmaceuticals Intl. Inc. Research Report

On July 15, 2013, Valeant Pharmaceuticals Intl. Inc. (Valeant) announced that
it will discuss its financial results for Q2 2013 via conference call and live
Internet webcast on Wednesday, August 7, 2013 at 8:00 a.m. ET (5:00 p.m. PT).
Valeant informed that the webcast can be accessed at its website, and an
online archive of the webcast will be available following the end of the live
call, also at the Company's website. The Full Research Report on Valeant
Pharmaceuticals Intl. Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

--

Elan Corporation, plc. Research Report

On July 17, 2013, Elan Corporation, plc. (Elan) announced that the US Food and
Drug Administration (FDA) has granted Fast Track Designation to its
development program of ELND005. The Company reported that ELND005 was
submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer's
disease (AD). As per Elan, its ongoing ELND005 clinical program includes the
Phase 2 Study AG201 in patients with AD, who are experiencing at least
moderate levels of agitation/aggression and the safety extension Study AG251.
In other news dated July 10, 2013, Elan announced that it will release its Q2
2013 financial results on Wednesday, July 24, 2013 before the European and
U.S. financial markets open, and hold a conference call at 8:30 a.m. ET/1:30
p.m. British Summer on the same day. The Full Research Report on Elan
Corporation, plc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e996_ELN]

--

Alkermes Plc. Research Report

On July 18, 2013, Alkermes plc. (Alkermes) announced that it will discuss its
Q2 2013 financial results via conference call on Thursday, July 25, 2013 at
8:30 a.m. EDT. The Company informed that a replay of the conference call will
be available from 10:30 a.m., July 25, 2013 through August 1, 2013. In other
news, dated July 17, 2013, Alkermes announced the initiation of a phase 2
study of its novel oral atypical drug candidate - ALKS3831 - designed to be a
broad spectrum treatment for schizophrenia. "We have designed ALKS 3831 as a
broad spectrum schizophrenia agent addressing two specific patient
subpopulations: patients who may benefit from attenuation of the significant
weight gain often associated with olanzapine treatment; and patients with a
dual diagnosis of substance abuse disorder, which often exacerbates their
schizophrenia," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes.
"This large, well-designed phase 2 study will provide data necessary for us to
determine ALKS 3831's ability to attenuate weight gain commonly associated
with olanzapine treatment." The Full Research Report on Alkermes Plc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e2f3_ALKS]

--

Teva Pharmaceuticals Industries Ltd. Research Report

On July 16, 2013, Teva Pharmaceuticals Industries Ltd. (Teva) announced that
it has scheduled to release its Q2 2013 financial results on Thursday, August
1, 2013 at 7:00 a.m. ET. A conference call, live webcast and Q&A session will
follow on the same day at 8:00 a.m. ET. Teva also informed that a replay of
the webcast will be available within 24 hours on the Company's website until
August 8, 2013, 11:59 p.m ET. The Full Research Report on Teva Pharmaceuticals
Industries Ltd. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

--

Gilead Sciences, Inc. Research Report

On July 18, 2013, Gilead Sciences, Inc. (Gilead) announced that it will
release its Q2 2013 financial results on Thursday, July 25, 2013 at 4:05 p.m.
ET. A conference call to discuss the Company's financial results and general
business updates will be hosted by Gilead's management and will be held at
4:30 p.m. on the same day. The conference call will be on the Company's
website. The Full Research Report on Gilead Sciences, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9898_GILD]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://analystscorner.com 

 

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement